Bonum Certa Men Certa

Insensitivity at the EPO's Management - Part II: Patent Office as a Cancer

Cancer letter



Summary: The EPO's stance on cancer recalled, in light of an altercation from 2013 (patent application no. EP03017743.0, appeal number T0598/12-3.3.02)

THE management of the EPO has resorted to what we consider both unethical and potentially illegal tactics. Union busting has taken such a high priority that every trick out of the book has been harnessed, with help from external (contracted) firms.

During Christmas we were contacted by a person who is able to show us just how jaw-dropping the EPO's management can be with regards (or disregard) to cancer. As a preparatory item, consider the following letter, which is nearly a couple of years old (emphasis with large fonts is ours):

Brussels, March 12th, 2014

M. Benoît Battistelli President - European Patent Office Erhardtstr. 27 80469 Munich Germany

Dear M. Battistelli,

My name is Francesco De Lorenzo and I am the President of the European Cancer Patient Coalition - ECPC, which represents 345 cancer patient organizations in 47 countries.

ECPC regularly engages with its members, EU institutions and international health and cancer care stakeholders to protect and enhance cancer patients’ rights in Europe, making sure that the voice of European citizens, affected by cancer, is heard.

That is why we are addressing you to express our concerns regarding the recent decision from the European Patent Office (EPO), Patent application no. EP03017743.0, appeal number T0598/12-3.3.02 on whether a clinical trial invalidates the request for a new drug patent.

"That is why we are addressing you to express our concerns regarding the recent decision from the European Patent Office (EPO), Patent application no. EP03017743.0, appeal number T0598/12-3.3.02 on whether a clinical trial invalidates the request for a new drug patent."We believe that EPO’s position on the matter should take in due consideration the effects it will have on the future treatment of cancer patients and their ability to dispose of new and innovative drugs. We are concerned, in fact, that EPO’s current interpretation of the matter may make clinical trials more difficult to carry out and hence undermine critical innovation in medicine.

Clinical trials are research studies conducted on patients to evaluate the safety and efficacy of medicines intended to improve their health and provide the necessary scientific data and information to develop new medicines. ECPC believes that patent policy should encourage innovation, particularly innovation arising from clinical trials. A clinical trial cannot and should not be construed as a patent defeating disclosure. Should this happen, there will eventually be serious implications for the development of life-saving medicines.

"We are concerned, in fact, that EPO’s current interpretation of the matter may make clinical trials more difficult to carry out and hence undermine critical innovation in medicine."Patients are not only a fundamental partner in the development of new drugs, but they are also those who will finally benefit from the innovation process. In particular, we strongly believe that it is natural that a patient may discuss his/her participation or clinical experience with their physician and family members. It is clear that patients participating in clinical trials should not be considered as members of the public, but rather key collaborators and important and voluntary participants of the trial. However, given their particular situation and knowledge level, patients cannot be compared either to other clinical trials actors, such as researchers. Hence patients cannot share the same confidentiality responsibility as researchers: this would, in fact, represent an unfair burden over the patients’ shoulders, which does not match patients’ level of biomedical and scientific understanding of clinical trials nor the reason for which they participate in them.

"ECPC believes that patent policy should encourage innovation, particularly innovation arising from clinical trials. A clinical trial cannot and should not be construed as a patent defeating disclosure."Aside from the pure legal perspective, it is to be expected that EPO decision on the 2013 case mentioned before, if implemented, will lead to reduced transparency and/or delay of implementation of new clinical trials, which are both to the detriment of patients’ interests. Reducing transparency will threaten the access to investigational drugs that clinical trials provide for patients. This access is of critical importance for cancer patients, particularly for those whose only treatment option may be a clinical trial.

Alternatively, delaying clinical trials until patent applications are filed, will add undue delay to the very time consuming process of developing a new medicine that could improve patients’ lives. Such patent policy also excludes any innovation that arises during a clinical trial.

"Aside from the pure legal perspective, it is to be expected that EPO decision on the 2013 case mentioned before, if implemented, will lead to reduced transparency and/or delay of implementation of new clinical trials, which are both to the detriment of patients’ interests."In conclusion, we strongly believe that the invention or findings related to a clinical trial should not be considered as “made available to the public” only because patients participate actively to the aforementioned trial. The patients’ unique status, in between collaborators and beneficiaries, makes them a key and vulnerable stakeholder, whose necessities are to be protected. Therefore, we would be glad to engage with EPO and all other relevant stakeholders in order to re-discuss the legal status and responsibilities of patients enrolled in clinical trials.

ECPC also believes that research should be encouraged and that public policy should remove barriers to the conduct of clinical trials, while keeping very high security standards and ensuring ethical conduct.

We hope that you will re-examine the decision in question for the benefit of patients. We remain at your disposal to further discuss the issue.

Sincerely,

Prof. F. De Lorenzo



To see how this relates to the series as a whole stay tuned for future parts. It is clear that patent scope has gone awry at the EPO, for the sake of protectionism, greed, and profit. Remember this when the EPO make claims on "productivity" (however misleading these claims can be) and ponder what this really translates into.

Recent Techrights' Posts

Microsoft's Attack Dogs Have Failed. Now What?
It would be utterly foolish to assume that Microsoft has any intention of changing
All Your "Github Projects" Will be Gone One Day (Just Like Skype)
If you have code you wish to share and keep, then start learning how to do so on your own
Fedora Already Lost Its Soul Under IBM
Fedora used to be very strict compared to many other distros and it had attracted very bright volunteers
Links 17/04/2025: Calling Whistleblowers at Microsoft, Slop Doing More Harm Everywhere
Links for the day
 
Links 18/04/2025: Layoffs at Microsoft Infosys and Qt Becoming Increasingly Proprietary (Plus Slop)
Links for the day
Google News is Dying
treating MElon's algorithmic/biased site as a source of verified news
To Understand Who's Truly Controlling You Follow the Trail of Censorship (or Self-Censorship)
Do not let media steal and steer the narrative; CoCs are not about "social justice", they're about corporate domination
Microsoft is Still Attacking GNU/Linux and the Net
Microsoft bribed the government using money that did not even exist
Over at Tux Machines...
GNU/Linux news for the past day
IRC Proceedings: Thursday, April 17, 2025
IRC logs for Thursday, April 17, 2025
Gemini Links 18/04/2025: Pinephone Pro and Linux is too Easy
Links for the day
Links 17/04/2025: Russian Bot Farms Infect TikTok (Which US Government and SCOTUS Decided to Block January 19), US Hardware Stocks Crash Due to Tariffs
Links for the day
Gemini Links 17/04/2025: Sticking to Free Software, Smolnet, and Counting the Reals
Links for the day
Open Source Initiative (OSI) Privacy Fiasco in Detail: In Conclusion and Enforcement Action Proceeds Against OSI at the California Privacy Protection Agency (CPPA)
There's too much to cover in one single part
When You Fail to Filter Your Clients You End Up SLAPPing Reporters on Behalf of Bad People From Microsoft in Another Continent
“American Psycho”
Links 17/04/2025: LayoffBot and Tesla Cheats Buyers
Links for the day
Gemnini Links 17/04/2025: Role of Language and Back to Mutt for E-mail
Links for the day
Over at Tux Machines...
GNU/Linux news for the past day
IRC Proceedings: Wednesday, April 16, 2025
IRC logs for Wednesday, April 16, 2025
Trump Authority (CA) With a Trump NSA is All About Security, But Whose?
A "turnkey tyranny", as the NSA whistleblower Thomas Drake loved to call it
Confirming IBM Shutdowns and Layoffs Today
It's not over yet
Gemini Links 16/04/2025: The 2010s Are Calling and Why "Tools Will Not Liberate Us"
Links for the day
You Should Probably Self-Host Your E-mail and Never Use a Web Browser for Mail
Does anyone still believe Gmail is "free"?
Links 16/04/2025: Cliff Lynch RIP, More Attacks on Science (NASA)
Links for the day
StatCounter Shows the Market Share of Vista 11 is Decreasing in Ukraine This Year
Microsoft abandoning Vista 10 users would be a victory for Vladimir Putin
Google Promotes Fake Articles (LLM Slop) Instead of Originals, Relaying Microsoft's Linux FUD Emanating From Microsoft LLMs
Shame on Google for participating in the slopfest
In Some Countries the Largest OEMs Already Dump Microsoft Windows
Windows at 18.9%, Android 60.2%
The "Gold" Rule: Taking Money for Reputation Laundering and Openwashing Under the "Linux" Banner
Seller of expensive toilet paper, Jim Zemlin
LLM Slop Says Slop is "coming for white-collar jobs. Microsoft’s layoffs are just the start"
Look what the Web has become
Microsoft Down From 100% to 10% in Myanmar/Burma
only about 4% of Web requests in Myanmar/Burma come from Vista 11, soon to be the only "supported" version of Windows
Reporting Facts About Violence Against Women Deserves Awards, Not Frivolous Lawsuits and Threats
What is Microsoft's stance on women's safety?
Linux.com as Spamfarm of the Linux Foundation, Partner of the Gates Foundation
They no longer publish articles
When Fedora Said It Was Looking to Integrate "AI" It Meant Promoting Microsoft's Proprietary Spyware and GPL-Violating Slop
When they say "AI" they mean Microsoft
Slopwatch: The Typical Slopfarms and the 'Brian Fagioli Dilemma'
To the Web and to society (exposed to the Web) LLMs are a net negative
It Used to be IBM, Now It's Microsoft (Why You Need to Fire Microsofters or CIOs Working for Microsoft)
Typically the only effective solution is to identity and remove Microsofters from one's project/organisation (before they can bring more Microsofters in)
IBM Closes Offices and Labs in the United States to Open New Ones in India
It's not layoffs per se; they're substituting/swapping veteran employees for lesser-paid ones
Over at Tux Machines...
GNU/Linux news for the past day
IRC Proceedings: Tuesday, April 15, 2025
IRC logs for Tuesday, April 15, 2025
Gemini Links 16/04/2025: IndieWeb Carnival, Tinylog RFC, "Focus, the Web and Gemini"
Links for the day